Exclusive Summary

• Highly potential Best-in-Class targeted mechanism: UB661 is a GLP-1R/GIPR/GCGR triple agonist polypeptide, poised to be a next-generation blockbuster in the obesity and diabetes space.
• Superior in vivo efficacy against the global frontrunner: In db/db and DIO mouse models, UB661 outperformed the late-stage competitor Retatrutide in both blood glucose control and weight reduction, achieving equivalent efficacy at only half the dosage.
• Exceptional dosing compliance and commercial barrier: The administration frequency can be extended to once-weekly or potentially bi-weekly (once every two weeks), significantly surpassing current once-weekly subcutaneous standards.
• De-risked safety profile with rapid development progress: The Rhesus monkey Dose Range Finding (DRF) study revealed no abnormalities, proving excellent safety, and the asset is rapidly advancing toward IND submission, making it an optimal candidate for out-licensing.

Asset Materials

Contact Us for Full Materials